Sara Labiano

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3436300/publications.pdf

Version: 2024-02-01

28 papers	2,207 citations	361413 20 h-index	501196 28 g-index
28 all docs	28 docs citations	28 times ranked	4584 citing authors

#	Article	IF	Citations
1	Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas. JCI Insight, 2022, 7, .	5.0	14
2	Fibroblast Activation Protein Î±-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity. Clinical Cancer Research, 2021, 27, 4036-4053.	7.0	31
3	CD40 Agonist Targeted to Fibroblast Activation Protein Î± Synergizes with Radiotherapy in Murine HPV-Positive Head and Neck Tumors. Clinical Cancer Research, 2021, 27, 4054-4065.	7.0	18
4	Enhanced Phenotype Definition for Precision Isolation of Precursor Exhausted Tumor-Infiltrating CD8 T Cells. Frontiers in Immunology, 2020, 11, 340.	4.8	27
5	Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells. Cancer Cell, 2019, 36, 613-629.e7.	16.8	99
6	Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation. Cancer Immunology Research, 2018, 6, 798-811.	3.4	62
7	Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4â€“1BB). OncoImmunology, 2018, 7, e1368605.	4.6	7
8	CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cellâ€“Relevant Genes. Cancer Immunology Research, 2018, 6, 69-78.	3.4	34
9	Tumor Resident Memory T Cells: New Players in Immune Surveillance and Therapy. Frontiers in Immunology, 2018, 9, 2076.	4.8	76
10	Intratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virusâ€“Derived Vectors Fosters Dendritic Cellâ€“Mediated T-cell Cross-Priming. Cancer Research, 2018, 78, 6643-6654.	0.9	60
11	CD69 is a direct HIF-1Î± target gene in hypoxia as a mechanism enhancing expression on tumor-infiltrating T lymphocytes. OncoImmunology, 2017, 6, e1283468.	4.6	27
12	Cellular immunotherapies for cancer. OncoImmunology, 2017, 6, e1306619.	4.6	17
13	Deciphering CD137 (4â€1BB) signaling in Tâ€cell costimulation for translation into successful cancer immunotherapy. European Journal of Immunology, 2016, 46, 513-522.	2.9	104
14	Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming. Cancer Research, 2016, 76, 5994-6005.	0.9	191
15	Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism. OncoImmunology, 2016, 5, e1062967.	4.6	52
16	Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Antiâ€“PD-1 and Anti-CD137 Monoclonal Antibodies. Journal of Thoracic Oncology, 2016, 11, 524-536.	1.1	48
17	Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs). Clinical Cancer Research, 2016, 22, 3924-3936.	7.0	306
18	Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Antiâ€“PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells. Cancer Discovery, 2016, 6, 71-79.	9.4	356

#	Article	IF	Citations
19	Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 7551-7556.	7.1	92
20	Immune Response Regulation in the Tumor Microenvironment by Hypoxia. Seminars in Oncology, 2015, 42, 378-386.	2.2	121
21	Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2â^'/â^'IL2RÎ³null Immunodeficient Mice. Cancer Research, 2015, 75, 3466-3478.	0.9	137
22	Virotherapy with a Semliki Forest Virusâ€"Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade. Cancer Immunology Research, 2015, 3, 449-454.	3.4	88
23	Functional expression of CD137 (4-1BB) on T helper follicular cells. OncoImmunology, 2015, 4, e1054597.	4.6	15
24	Combinations of immunostimulatory antibodies with synergistic effects against spontaneous cancer. OncoImmunology, 2014, 3, e27812.	4.6	3
25	Orchestrating immune check-point blockade for cancer immunotherapy in combinations. Current Opinion in Immunology, 2014, 27, 89-97.	5.5	111
26	Better Performance of CARs Deprived of the PD-1 Brake. Clinical Cancer Research, 2013, 19, 5546-5548.	7.0	11
27	Combined Immunostimulatory Monoclonal Antibodies Extend Survival in an Aggressive Transgenic Hepatocellular Carcinoma Mouse Model. Clinical Cancer Research, 2013, 19, 6151-6162.	7.0	92
28	LIF, a Novel STAT5-Regulated Gene, Is Aberrantly Expressed in Myeloproliferative Neoplasms. Genes and Cancer, 2011, 2, 593-596.	1.9	8